Fluoride and Silver Pharmacokinetics of DSF Applied Topically to Teeth of Adults. Erythema, Bleeding, White Changes, Ulceration and Pigmentation Were AssessedPhase 1NCT01664871
Pharmacokinetics of Diammine Silver Fluoride
A Phase 1 study testing DIammine SIlver Fluoride in people with Fluoride and Silver Pharmacokinetics of DSF Applied Topically to Teeth of Adults. Erythema, Bleeding, White Changes, Ulceration and Pigmentation Were Assessed, run by Universidad Peruana Cayetano Heredia at 1 site in Peru.
Trial summary
There is growing worldwide interest in the use of diammine silver fluoride (DSF) as a topical agent to treat dentin hypersensitivity and dental caries. It has been available in various formulations for many years, but its safety profile has never been fully characterized. Read more about this study
- Who is it for?
- Ages 10 to 60 yearsHealthy volunteers can take part
- Conditions the study is for
- Fluoride and Silver Pharmacokinetics of DSF Applied Topically to Teeth of Adults. Erythema, Bleeding, White Changes, Ulceration and Pigmentation Were Assessed
- What is being tested?
- DIammine SIlver Fluoride
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 6 participants
- Where
- 1 sitePeru
- Study dates
- Jul 2011to Sep 2011
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 10 to 60 years
- All sexes
- Healthy volunteers accepted
- Child, Adult
Who may be able to join
- Subjects with dental abfraction, erosion or root caries at least in one upper or lower premolar or molar
- Those teeth should have hypersensitivity with cold air
Who cannot join
- Use of any type of hypersensitivity toothpaste
- Use of pain medication
- Pregnant women
- Individuals with sensitivity to silver or other metal ions
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Characterization of Fluoride and Silver Pharmacokinetics of Diammine Silver Fluoride Applied Topically to Teeth of Adults
There is growing worldwide interest in the use of diammine silver fluoride (DSF) as a topical agent to treat dentin hypersensitivity and dental caries. It has been available in various formulations for many years, but its safety profile has never been fully characterized.
This preliminary study determined the applied doses (3 teeth treated), maximum serum concentrations, and time to maximum serum concentration for fluoride and silver in 6 adults over 4 h. Fluoride was determined using the indirect diffusion method with a fluoride selective electrode, and silver was determined using inductively coupled plasma-mass spectrometry. The mean amount of DSF solution applied to the 3 teeth was 7.57 mg (6.04 µL).
.
Read the detailed description
Participants Six healthy volunteers (4 females, mean age 36.2, range 23-52 yr) were recruited among staff members of the Universidad Católica de Santa María, Arequipa, Peru. Participants were taking no medications and had most permanent teeth present. Participants were asked to avoid fish or tea for 12 h before the study and not use fluoridated toothpaste 4 h prior. The Comité de Etica de Investigacion, Universidad Católica de Santa María approved the study and informed consent was obtained.
Study Agent DSF [Ag(NH3)2F, CAS RN 33040-28-7, Saforide, Toyo Seiyaku Kasei Co. Ltd. Osaka, Japan] was used. DSF is clear and colorless, with a weak odor of ammonia. The 38% solution contains between 24.4-28.8% (w/v) silver (Ag), and 5.0-5.9% fluoride (F). Concentrations of Ag and F in the DSF used for study were 24.9% and 5.5%, respectively, and the specific gravity was 1.253 at 25°C (Certificate of Analysis Lot #155060). Diammine silver fluoride is also referred to in the literature as silver diammine fluoride, silver diamine fluoride or silver fluoride.
Procedures Three maxillary teeth (cuspid and premolars) in the same quadrant were treated. Three teeth were treated because this was the average number of sensitive teeth reported in an epidemiological study of adults [5]. The teeth were free of restorations or cavitation. The facial surface was dried with cotton gauze and then DSF was applied to the cervical area of each tooth. The teeth were isolated in order to avoid wetting the brush with saliva. Each tooth was coated using a separate microbrush, which was dipped in the DSF and weighed before and after the application (Model S2000, Kern \& Sohn GmbH, Balingen, Germany). The sum of the differences in weight of material applied was calculated for each participant.
Blood Collection Immediately before application of DSF and then again at approximately 30 min, 1, 2,3 and 4 h after application, blood was obtained from a peripheral vein. The time periods were picked based on a previous pharmacokinetics study of fluoride varnish [6]. The blood was transferred to a fluoride-free plastic Vacutainer tube with clot activator (BD Vacutainer Plus Plastic Serum Tube, BD Diagnostics, New Jersey). The tubes were spun at 1100 g for 10 min and serum transferred by plastic pipette to plastic cryogenic tubes. The samples were frozen and transported to the University of Washington for analysis.
Analysis Fluoride. Samples were thawed and analyzed in duplicate or triplicate using the diffusion and detection method with hexamethyldisiloxane (HMDS) and Orion F-sensitive electrode [7-8]. To improve detection, the pre-diffusion step was omitted [9], and seals were completed before mixing 1 mL serum with 1 mL HMDS, saturated 3 M H2SO4 [10]. The trapping solution was 20 µmoles 1 M NaOH. It was dried down to eliminate variability of evaporation and residual HMDS before adding 100 µL 3 M acetic acid to a final pH 3.4. Standards were 10 and 100 µM fluoride in the same final concentration of NaOH and acetic acid corresponding to 1 and 10 µM F in the samples. ORION F and sleeve type reference electrodes were coupled with an Accumet Basic 0.1 mV meter (Thermo Fisher Scientific, Milwaukee WI).
Vacutainers were tested for fluoride by adding bovine plasma to 2 tubes and letting them sit overnight before combining the 2 samples and comparing them to plasma directly placed in diffusion dishes. Average concentrations (μM±SD) were 0.34±0.014 and 0.32±0.012, respectively. Therefore, less than 2% F in the serum samples came from the Vacutainers and clot enhancer. Recovery (mean±SD) of 1 nmole/ml F added to bovine serum was 101±4%. Fluoride levels were averaged and are expressed as µM.
Silver. Samples were thawed and analyzed using Inductively Coupled Plasma-Mass Spectrometry (EPA 6020a Rev.1 2007). Serum (0.5 mL) was brought to 2 mL with dilute acid (final concentration: 2% HCl, 1% HNO3; trace metal grade, Fisher, Fairlawn, NJ). Samples were centrifuged (1290 g) for 10 min and filtered (0.45 µm, PTFE; all polypropylene syringe) into 15 mL polypropylene centrifuge tubes. The samples were analyzed on an Agilent 7500CE (Santa Clara, CA) inductively-coupled mass spectrometer (ICPMS) with He as the collision cell gas and an ASX-510 autosampler (CETAC, Omaha, NB). A Micromist nebulizer (Glass Expansion, Pocasset, MA) was used (1.15 L/min carrier gas; no makeup gas). Spray chamber temperature was 2°C. RF power was 1500 W. Ag was quantified using Y as internal standard. Calibrants were diluted with 2% HCl and 1% HNO3 prepared from commercial ICPMS grade solutions (Ultra Scientific, N. Kingstown, RI; BDH Aristar, VWR, Radnor, PA) and ranged from 0.5-50 ng/mL. Calibration was by weighted (1/cps) linear regression. Data was corrected by procedure blank. Values of silver less than 2 ng/mL were recoded to 2. Silver concentrations are expressed as ng/mL.
Soft Tissue Assessment The gingiva adjacent to the application of DSF and the mucosa generally were observed at baseline and 24 h after treatment. Erythema, bleeding, white changes, ulceration and pigmentation were assessed using methods developed for an earlier study [1].
- Being tested
- DIammine SIlver Fluoride
- Medical subject headings
- Hemorrhage, Ulcer
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
DIammine SIlver FluorideDevice
Concentrations of Silver and Fluoride in the DSF used for study were 24.9% and 5.5%, respectively Average total weight (calculated volume) of Diammine Silver Fluoride applied was 7.57 mg (6.04 µL), corresponding to a mean application of 0.33 mg Fluoride based on the lot analysis. The mean total amount of Silver applied to the 3 teeth was 1.50 mg.
| Study group | Role | What they receive |
|---|---|---|
| Levels of SIlver and Fluoride in Plasma | Experimental | Not described Receives: Device: DIammine SIlver Fluoride |
What is being measured
The primary outcome is the main question the study is designed to answer.
Level of Fluoride in Plasma
Samples were thawed and analyzed in duplicate or triplicate using the diffusion and detection method with hexamethyldisiloxane (HMDS) and Orion F-sensitive electrode
Measured: baseline, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours
Level of Silver in Plasma
Samples were thawed and analyzed using Inductively Coupled Plasma-Mass Spectrometry
Measured: baseline, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours
Secondary outcomes (1)
Gingival alterations
The gingiva adjacent to the application of DSF and the mucosa generally were observed at baseline and 24 h after treatment. Erythema, bleeding, white changes, ulceration and pigmentation were assessed using methods developed for an earlier study
Measured: baseline, immediately after treatment, 24 hours after treatment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Aug 2012 (estimated)
- Study startJul 2011
- Primary completionAug 2011
- Study completionSep 2011
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Fluoride and Silver Pharmacokinetics of DSF Applied Topically to Teeth of Adults. Erythema, Bleeding, White Changes, Ulceration and Pigmentation Were AssessedStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 6 participants (actual)
Sponsor and investigators
- Lead sponsor
- Universidad Peruana Cayetano Heredia
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Peter Milgrom, DDS, Principal investigator, University of WashingtonElsa Vasquez, DDS, Study director, Universidad Catolica Santa Maria ArequipaJorge Castillo, DDS MSD PhD, Study chair, Universidad Peruana Cayetano Heredia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01664871
- Sponsor's protocol ID
- UC1110
- Status last verified
- Aug 2012
- First submitted
- 10 Aug 2012
- Last updated
- 14 Aug 2012
- Results posted
- No
- Data monitoring committee
- No
Publications
Vasquez E, Zegarra G, Chirinos E, Castillo JL, Taves DR, Watson GE, Dills R, Mancl LL, Milgrom P. Short term serum pharmacokinetics of diammine silver fluoride after oral application. BMC Oral Health. 2012 Dec 31;12:60. doi: 10.1186/1472-6831-12-60.
PubMed 23272643
Study at a glance
From the registry record, last updated by the sponsor on 14 Aug 2012. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Characterization of Fluoride and Silver Pharmacokinetics of Diammine Silver Fluoride Applied Topically to Teeth of Adults
- ClinicalTrials.gov ID
- NCT01664871
- Acronym / sponsor ID
- UC1110
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 6 participants (actual)
- Lead sponsor
- Universidad Peruana Cayetano HerediaUniversity, hospital or other
- Study start
- Jul 2011
- Primary completion
- Aug 2011 (actual)
- Study completion
- Sep 2011 (actual)
- First posted
- 14 Aug 2012 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
There is growing worldwide interest in the use of diammine silver fluoride (DSF) as a topical agent to treat dentin hypersensitivity and dental caries. It has been available in various formulations for many years, but its safety profile has never been fully characterized.
This preliminary study determined the applied doses (3 teeth treated), maximum serum concentrations, and time to maximum serum concentration for fluoride and silver in 6 adults over 4 h. Fluoride was determined using the indirect diffusion method with a fluoride selective electrode, and silver was determined using inductively coupled plasma-mass spectrometry. The mean amount of DSF solution applied to the 3 teeth was 7.57 mg (6.04 µL).
.
Detailed description
Participants Six healthy volunteers (4 females, mean age 36.2, range 23-52 yr) were recruited among staff members of the Universidad Católica de Santa María, Arequipa, Peru. Participants were taking no medications and had most permanent teeth present. Participants were asked to avoid fish or tea for 12 h before the study and not use fluoridated toothpaste 4 h prior. The Comité de Etica de Investigacion, Universidad Católica de Santa María approved the study and informed consent was obtained.
Study Agent DSF [Ag(NH3)2F, CAS RN 33040-28-7, Saforide, Toyo Seiyaku Kasei Co. Ltd. Osaka, Japan] was used. DSF is clear and colorless, with a weak odor of ammonia. The 38% solution contains between 24.4-28.8% (w/v) silver (Ag), and 5.0-5.9% fluoride (F). Concentrations of Ag and F in the DSF used for study were 24.9% and 5.5%, respectively, and the specific gravity was 1.253 at 25°C (Certificate of Analysis Lot #155060). Diammine silver fluoride is also referred to in the literature as silver diammine fluoride, silver diamine fluoride or silver fluoride.
Procedures Three maxillary teeth (cuspid and premolars) in the same quadrant were treated. Three teeth were treated because this was the average number of sensitive teeth reported in an epidemiological study of adults [5]. The teeth were free of restorations or cavitation. The facial surface was dried with cotton gauze and then DSF was applied to the cervical area of each tooth. The teeth were isolated in order to avoid wetting the brush with saliva. Each tooth was coated using a separate microbrush, which was dipped in the DSF and weighed before and after the application (Model S2000, Kern \& Sohn GmbH, Balingen, Germany). The sum of the differences in weight of material applied was calculated for each participant.
Blood Collection Immediately before application of DSF and then again at approximately 30 min, 1, 2,3 and 4 h after application, blood was obtained from a peripheral vein. The time periods were picked based on a previous pharmacokinetics study of fluoride varnish [6]. The blood was transferred to a fluoride-free plastic Vacutainer tube with clot activator (BD Vacutainer Plus Plastic Serum Tube, BD Diagnostics, New Jersey). The tubes were spun at 1100 g for 10 min and serum transferred by plastic pipette to plastic cryogenic tubes. The samples were frozen and transported to the University of Washington for analysis.
Analysis Fluoride. Samples were thawed and analyzed in duplicate or triplicate using the diffusion and detection method with hexamethyldisiloxane (HMDS) and Orion F-sensitive electrode [7-8]. To improve detection, the pre-diffusion step was omitted [9], and seals were completed before mixing 1 mL serum with 1 mL HMDS, saturated 3 M H2SO4 [10]. The trapping solution was 20 µmoles 1 M NaOH. It was dried down to eliminate variability of evaporation and residual HMDS before adding 100 µL 3 M acetic acid to a final pH 3.4. Standards were 10 and 100 µM fluoride in the same final concentration of NaOH and acetic acid corresponding to 1 and 10 µM F in the samples. ORION F and sleeve type reference electrodes were coupled with an Accumet Basic 0.1 mV meter (Thermo Fisher Scientific, Milwaukee WI).
Vacutainers were tested for fluoride by adding bovine plasma to 2 tubes and letting them sit overnight before combining the 2 samples and comparing them to plasma directly placed in diffusion dishes. Average concentrations (μM±SD) were 0.34±0.014 and 0.32±0.012, respectively. Therefore, less than 2% F in the serum samples came from the Vacutainers and clot enhancer. Recovery (mean±SD) of 1 nmole/ml F added to bovine serum was 101±4%. Fluoride levels were averaged and are expressed as µM.
Silver. Samples were thawed and analyzed using Inductively Coupled Plasma-Mass Spectrometry (EPA 6020a Rev.1 2007). Serum (0.5 mL) was brought to 2 mL with dilute acid (final concentration: 2% HCl, 1% HNO3; trace metal grade, Fisher, Fairlawn, NJ). Samples were centrifuged (1290 g) for 10 min and filtered (0.45 µm, PTFE; all polypropylene syringe) into 15 mL polypropylene centrifuge tubes. The samples were analyzed on an Agilent 7500CE (Santa Clara, CA) inductively-coupled mass spectrometer (ICPMS) with He as the collision cell gas and an ASX-510 autosampler (CETAC, Omaha, NB). A Micromist nebulizer (Glass Expansion, Pocasset, MA) was used (1.15 L/min carrier gas; no makeup gas). Spray chamber temperature was 2°C. RF power was 1500 W. Ag was quantified using Y as internal standard. Calibrants were diluted with 2% HCl and 1% HNO3 prepared from commercial ICPMS grade solutions (Ultra Scientific, N. Kingstown, RI; BDH Aristar, VWR, Radnor, PA) and ranged from 0.5-50 ng/mL. Calibration was by weighted (1/cps) linear regression. Data was corrected by procedure blank. Values of silver less than 2 ng/mL were recoded to 2. Silver concentrations are expressed as ng/mL.
Soft Tissue Assessment The gingiva adjacent to the application of DSF and the mucosa generally were observed at baseline and 24 h after treatment. Erythema, bleeding, white changes, ulceration and pigmentation were assessed using methods developed for an earlier study [1].
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Levels of SIlver and Fluoride in Plasma | Experimental | Device: DIammine SIlver Fluoride |
Who may qualify
- Ages
- 10 to 60 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult
Key inclusion criteria (2 listed)
- Subjects with dental abfraction, erosion or root caries at least in one upper or lower premolar or molar
- Those teeth should have hypersensitivity with cold air
Key exclusion criteria (4 listed)
- Use of any type of hypersensitivity toothpaste
- Use of pain medication
- Pregnant women
- Individuals with sensitivity to silver or other metal ions
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| DIammine SIlver FluorideConcentrations of Silver and Fluoride in the DSF used for study were 24.9% and 5.5%, respectively Average total weight (calculated volume) of Diammine Silver Fluoride applied was 7.57 mg (6.04 µL), corresponding to a mean application of 0.33 mg Fluoride based on the lot analysis. The mean total amount of Silver applied to the 3 teeth was 1.50 mg. | Device | Levels of SIlver and Fluoride in Plasma |
Primary outcome
Level of Fluoride in Plasma
Time frame: baseline, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours
Samples were thawed and analyzed in duplicate or triplicate using the diffusion and detection method with hexamethyldisiloxane (HMDS) and Orion F-sensitive electrode
Level of Silver in Plasma
Time frame: baseline, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours
Samples were thawed and analyzed using Inductively Coupled Plasma-Mass Spectrometry
1 secondary outcome
Gingival alterations
Time frame: baseline, immediately after treatment, 24 hours after treatment
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Aug 2012.
- Derived from this study: PubMed 23272643Vasquez E, Zegarra G, Chirinos E, Castillo JL, Taves DR, Watson GE, Dills R, Mancl LL, Milgrom P. Short term serum pharmacokinetics of diammine silver fluoride after oral application. BMC Oral Health. 2012 Dec 31;12:60. doi: 10.1186/1472-6831-12-60.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Peter Milgrom, DDS principal investigator
University of Washington
Elsa Vasquez, DDS study director
Universidad Catolica Santa Maria Arequipa
Jorge Castillo, DDS MSD PhD study chair
Universidad Peruana Cayetano Heredia
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing DIammine SIlver Fluoride in people with Fluoride and Silver Pharmacokinetics of DSF Applied Topically to Teeth of Adults. Erythema, Bleeding, White Changes, Ulceration and Pigmentation Were Assessed, run by Universidad Peruana Cayetano Heredia at 1 site in Peru.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Aug 2012. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Peru. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Level of Fluoride in Plasma (time frame: baseline, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01664871, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Aug 2012.